What's needed for the next WHO Biosafety Handbook

April 19, 2018

In this Policy Forum, Kazunobu Kojima et al. highlight key issues that should be addressed through the next revision of the World Health Organization (WHO) Laboratory Biosafety Manual (LBM). First released in 1983, the LBM provides a valuable framework, which nations rely greatly on, for safely studying pathogenic microorganisms, such as Ebola virus. Yet the authors note that previous LBMs have largely a focused on engineering and building expensive labs with potential to handle heavy-duty pathogens; this checklist-like approach is unsustainable, the authors say, particularly in less developed countries that lack resources to maintain the facilities. Furthermore, a review of infections contracted in laboratories reveals that many are caused by human factors (e.g., improper personal protective equipment), a point that has been underemphasized in previous LBM versions. Therefore, better workforce development and training is just as important as infrastructure, the authors emphasize. They recommend that the upcoming fourth revision of the WHO LBM adopts a risk- and evidence-based approach to biosafety that ensures that laboratory facilities, safety equipment, and work practices are locally relevant, proportionate, and sustainable. The new LBM could include "core requirements," a combination of commonly known biosafety elements to be implemented and used, constituting a minimum requirement for safe work during the majority of laboratory procedures, the authors say.
-end-


American Association for the Advancement of Science

Related Biosafety Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Study shows first proof that a safer UV light effectively kills virus causing COVID-19
Researchers offer first proof that Ultraviolet C light with a 222 nm wavelength -- which is safer to use around humans -- effectively kills the SARS-CoV-2 virus.

Unveiled: A channel SARS-CoV-2 may use to proceed with viral replication in the host cell
By visualizing coronavirus replication in an infected host cell, researchers may have answered a long-standing question about how newly synthesized coronavirus components are able to be incorporated into fully infectious viruses.

Rapid test for the determination of antibodies against Sars-Cov-2
To determine immunity to Sars-Cov-2 and the effectiveness of potential vaccines, the amount of neutralising antibodies in the blood of recovered or vaccinated individuals must be determined.

Lab-made virus mimics COVID-19 virus
Researchers at Washington University School of Medicine in St. Louis have created a virus in the lab that infects cells and interacts with antibodies just like the COVID-19 virus, but lacks the ability to cause severe disease.

Researchers develop new tools to rapidly test activity of anti-coronavirus antibodies
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic.

Spraying ethanol to nanofiber masks makes them reusable
A joint research team from POSTECH and Japan's Shinshu University evaluates the filtration efficiency of nanofiber and melt-blown filters when cleaned with ethanol.

Biomedical sciences researchers provide methods to inactivate and safely study SARS-CoV-2
Detailed methods on how to perform research on SARS-CoV-2, the virus that causes COVID-19, including procedures that effectively inactivate the virus to enable safe study of infected cells have been identified by virologists in the Institute for Biomedical Sciences at Georgia State University.

Researchers identify a model of COVID-19 infection in nonhuman primates
After comparing how infections from SARS-CoV-2 (which causes COVID-19) and two other human coronaviruses develop in cynomolgus macaques, researchers report that SARS-CoV-2 gives the animals a mild COVID-19-like disease.

Read More: Biosafety News and Biosafety Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.